Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) 5 year CAGR for the year ending December 31, 2022

Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) 5 year CAGR is NA for the year ending December 31, 2022. Free Cash Flow to Firm represents the cash flow available to all capital providers, including both equity and debt holders. It considers the tax shield effect of interest expense. This ratio indicates the company's ability to generate cash flow available to all stakeholders, including interest payments to debt holders and returns to equity shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) for the year ending December 31, 2022 was USD -33.07 M, a -125.77% change year over year.
  • Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) for the year ending December 31, 2021 was USD 128.31 M, a 1,822.31% change year over year.
  • Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) for the year ending December 31, 2020 was USD -7.45 M, a -9.27% change year over year.
  • Acumen Pharmaceuticals Inc Free Cash Flow to Firm (FCFF) for the year ending December 31, 2019 was USD -6.82 M.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email